Deals: Page 19
-
Deals surge, returns slip: takeaways from a record half for biotech IPOs
Biotech initial public offerings could break records set just last year. But their average size and performance are declining, which some say might reflect an overdue correction.
By Ben Fidler • June 30, 2021 -
With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt
The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena.
By Jacob Bell • June 24, 2021 -
Courtesy of GSK Flickr page
GSK outlines ambitious 10-year plan, but hits investors' near-term outlook
Under pressure from activist investors, the British drugmaker set lofty sales targets for a "new GSK" after a planned exit from consumer health. But shareholders will first face a dividend cut.
By Jonathan Gardner • June 23, 2021 -
Permission granted by Bristol-Myers Squibb
Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody
The U.S. drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.
By Jonathan Gardner • June 18, 2021 -
Getty / Edited by BioPharma Dive
CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder
A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines.
By Jonathan Gardner • June 15, 2021 -
Warren Little via Getty Images
GSK pays iTeos $625M to join race for new type of cancer immunotherapy
The British drugmaker has become the latest large pharmaceutical company to make a sizable investment in a drug targeting TIGIT, following deals from Bristol Myers Squibb, Gilead and others.
By Ben Fidler • June 14, 2021 -
Brian Tucker/BioPharma Dive
Deep Dive'The lights are no longer green': Antitrust regulators reassess pharma deals
The FTC and its counterparts abroad are rethinking their approach to drugmaker acquisitions. Past scrutiny offers clues to where they may look next.
By Jonathan Gardner • June 10, 2021 -
Bayer buys a biotech and its offshoot in bet on radiopharmaceuticals
The German pharma will add an experimental prostate cancer medicine to its pipeline through the deal, which reflects growing industry interest in the field.
By Ned Pagliarulo • June 3, 2021 -
Elizabeth Regan/BioPharma Dive
MorphoSys to buy Constellation in $1.7B deal, aided by unusual funding
Royalty Pharma will effectively fund MorphoSys' acquisition of the cancer biotech through a separate agreement to buy MorphoSys' shares of royalties on several marketed and experimental medicines.
By Ned Pagliarulo • June 2, 2021 -
Permission granted by Biogen
Biogen licenses a stroke drug from Japanese drugmaker TMS
The drug, which Biogen had an option to license, is one of two in the biotech's pipeline for a condition that has had few new treatments developed.
By Kristin Jensen • May 12, 2021 -
Courtesy of Ginkgo Bioworks
Ginkgo Bioworks to go public through $2.5B SPAC deal
Bellco Capital, led by Kite Pharma and Allogene Therapeutics founder Arie Belldegrun, will co-sponsor the transaction alongside Eagle Equity Partners.
By Ned Pagliarulo • May 11, 2021 -
Getty / Edited by BioPharma Dive
CSL closes deal for UniQure gene therapy in hopeful sign for M&A
Completion of the buyout eases concerns the arrangement might be held up by the FTC, which has signaled it will step up scrutiny of life sciences deals.
By Kristin Jensen • May 6, 2021 -
Roivant valued at $7B in blank-check merger, bucking SPAC slowdown
Vivek Ramaswamy's unusual biotech holding company will go public through a deal with Montes Archimedes Acquisition Corp. that nets Roivant $611 million.
By Ben Fidler • May 3, 2021 -
Vertex bets another $900M on CRISPR treatment for blood diseases
Vertex and CRISPR Therapeutics are tweaking their partnership so that the larger biotech will cover 60% of the costs — and receive 60% of the future profits — related to a gene editing therapy for sickle cell disease and beta thalassemia.
By Jacob Bell • April 20, 2021 -
Permission granted by Relay Therapeutics
Relay buys AI startup to aid unorthodox drug discovery quest
The $85 million acquisition is an unusual and early step for a company like Relay, which went public last July and only just began clinical testing of its lead drugs last year.
By Ned Pagliarulo • April 16, 2021 -
Lisa Maree Williams via Getty Images
US clears AstraZeneca buyout of Alexion amid closer scrutiny of biopharma M&A
FTC authorization of the $39 billion deal — the sector's largest in 2020 — may ease concerns over the agency's plans to more intently inspect pharma deals.
By Jonathan Gardner • April 16, 2021 -
Elizabeth Regan/BioPharma Dive
Thermo Fisher to buy research contractor PPD in $17B deal
The deal values PPD at $47.50 a share, or about 24% over the company's closing price on April 13 — the day before The Wall Street Journal reported word of the planned acquisition.
By Kristin Jensen • April 15, 2021 -
Cancer biotech Tango to go public through $350M SPAC deal
Gilead, which expanded its research collaboration with Tango last year, will take part in a related private investment along with more than a dozen high-profile backers.
By Kristin Jensen • April 14, 2021 -
Courtesy of Sanofi
Sanofi buys an mRNA startup in another bet on 'off-the-shelf' cell therapy
Tidal Therapeutics is the second biotech developing more convenient cell therapies that the French pharma has recently acquired as part of a broader expansion in oncology.
By Ben Fidler • April 9, 2021 -
Amgen acquires a small biotech and its inflammatory disease research
The deal for Rodeo Therapeutics follows closely on the heels of the large biotech's buyout of cancer drug developer Five Prime.
By Kristin Jensen • March 31, 2021 -
FTC challenges Illumina's $7B Grail buyout amid new scrutiny of life science deals
The commission said the acquisition will "harm competition in the U.S. market" for early cancer detection tests.
By Nick Paul Taylor • March 31, 2021 -
Global Blood takes on more sickle cell drugs through Sanofi deal
Global Blood says the two acquired programs could complement Oxbryta, its marketed sickle cell drug that gained approval in late 2019.
By Jacob Bell • March 16, 2021 -
Brian Tucker/BioPharma Dive
FTC joins overseas antitrust regulators in reexamination of pharma M&A
Rebecca Kelly Slaughter, the commission's acting chair, indicated future reviews could look beyond measures of company size and market share.
By Jonathan Gardner • March 16, 2021 -
Elizabeth Regan/BioPharma Dive
Gilead, Merck combine forces in HIV
The rivals are now working together on oral and injectable treatments that combine their closely watched experimental drugs lenacapavir and islatravir.
By Jacob Bell • March 15, 2021 -
Taking a page from Celgene, Takeda builds and buys a cancer biotech
An agreement to acquire Maverick Therapeutics for up to $525 million has roots in a plan hatched by Takeda to emulate elements of Celgene's dealmaking strategy.
By Ben Fidler • March 9, 2021
Previous
